2025-04-28

Novamab will present the oral TL1A nanobody and long-acting TL1A bispecific antibody at the DDW 2025 conference

More

2025-03-25

Novamab Announces Successful Completion of LQ036 Phase IIa Clinical Trial Demonstrating Superior Efficacy and Safety – The World’s First Inhaled IL-4Rα Biologic Offers an Innovative Treatment Option for Asthma Patients

More

2024-12-19

Novamab has been listed on the 2024 Cyzone 100 Future Unicorn List

More

2024-12-13

Congratulations to Dr. Wan Yakun, founder of Novamab for being selected as the "Pearl Leading Talent" for Pudong New Area in 2024

More

2024-09-30

Novamab Ranks in the Top 10 Most Promising Biopharma Companies on the Huayi List 2024

More

2024-07-31

Novamab officially announced the completion of nearly 300 million RMB in Series B financing

More

2024-05-11

International Conference 及2024 BIO International Convention

More

2024-04-23

Novamab: LQ036 Completes The First Patient Dosing in Phase IIa Clinical StudyThe First Inhaled Biological Agent in China Provides A New Treatment Option for Asthma Patients

More

2024-03-05

BioCon 2024- "Research Progress of Inhalable Nanobody Drug Therapy for Asthma" A Brief Discussion on Differentiated Development of Antibody Drugs and Clinical Progress of Novamab

More

2024-02-29

Research Information - The development and scaling up of the production process of Novamab‘s anti TSLP Nanobody have reached an internationally leading level

More